TCS359 is a small molecule inhibitor of the Fms-like tyrosine kinase 3 (FLT3), which is a receptor tyrosine kinase that plays a critical role in the development and progression of acute myeloid leukemia (AML). In this article, we will discuss TCS359's chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.
Chemical name:
The chemical name of TCS359 is N-(4-((5-chloro-1H-indol-3-yl)amino)-5-cyano-6-methylpyridin-2-yl)-N-(2-hydroxyethoxy)urea.
Molecular formula:
The molecular formula of TCS359 is C19H18ClN7O3.
Formula weight:
The formula weight of TCS359 is 445.85 g/mol.
CAS No:
The CAS No of TCS359 is 301305-73-7.
Top ten keywords from Google and Synonyms Synonym:
Synonyms:
Health benefits of this product:
TCS359 is being developed as a potential treatment for acute myeloid leukemia (AML), which is a type of cancer that affects the bone marrow and blood. Preclinical studies have shown that the drug has potent anti-tumor activity against AML cells that harbor FLT3 mutations, which are present in about one-third of AML patients. The drug may also have the potential to overcome resistance to other AML treatments such as chemotherapy and targeted therapies.
Potential effects:
Since TCS359 is still in the early stages of clinical development, its potential effects are not yet fully understood. However, preclinical studies have demonstrated that it has potent anti-tumor activity against AML cells that harbor FLT3 mutations. The drug may also have the potential to overcome resistance to other AML treatments, such as chemotherapy and targeted therapies.
Product mechanism:
FLT3 is a receptor tyrosine kinase that is expressed on the surface of hematopoietic stem and progenitor cells. Dysregulation of FLT3 signaling has been implicated in the development and progression of AML. TCS359 works by inhibiting the activity of FLT3, thereby blocking downstream signaling pathways that promote AML cell growth and survival. This mechanism of action makes it a promising therapeutic option for the treatment of FLT3-mutant AML.
Safety:
As with all investigational drugs, the safety of TCS359 is still being evaluated in clinical trials. In preclinical studies, the drug was well-tolerated with no significant toxicities observed at therapeutic doses. However, adverse events such as nausea, vomiting, and fatigue have been reported in early clinical trials. Patients receiving TCS359 should be closely monitored for any signs of adverse reactions.
Side effects:
Common side effects of TCS359 may include nausea, vomiting, fatigue, and diarrhea. More serious side effects such as liver toxicity and cardiac events have been reported in some patients in early clinical trials. Patients receiving TCS359 should be closely monitored for any signs of adverse reactions and should report any symptoms to their healthcare provider.
Dosing information:
TCS359 is administered orally, and the recommended dose varies depending on the specific type of cancer being treated. Clinical trials are currently underway to determine the optimal dosing regimen for TCS359. Patients receiving TCS359 should follow their healthcare provider's instructions regarding dosing and administration.
Conclusion:
TCS359 is a promising new drug being developed as a potential treatment for acute myeloid leukemia (AML) that harbors FLT3 mutations. It works by inhibiting the activity of FLT3, thereby blocking downstream signaling pathways that promote AML cell growth and survival. While the drug is still in the early stages of clinical development, preclinical studies suggest that it has potent anti-tumor activity and may be able to overcome resistance to other AML treatments. However, more research is needed to fully understand its potential benefits, risks, and optimal dosing regimen
